Edgar D. Staren, MD, PhD, MBA

The early problems with novel technology such as excimer laser and rotational atherectomy were partly related to operator unfamiliarity Somewhat surprisingly pain solutions treatment center ga order rizatriptan overnight delivery, the incidence of coronary artery perforation has not changed significantly over two and a half decades knee pain treatment options rizatriptan 10 mg purchase line. The later studies include observational reports of practice using modern guide wire technology and antiplatelet drug regimens pain treatment for cats trusted rizatriptan 10 mg. The complexity of interventional cases has increased markedly over the past two decades pain syndrome treatment order online rizatriptan, and yet perforation rates have not pain treatment center of southwest georgia purchase rizatriptan 10 mg amex. Naturally there is a degree of variation in the incidence reported by the authors. This may, in part, be explained by a differing definition of coronary perforation for each article. Together with colleagues, the authors of this chapter reported an incidence of just under 0. Von Sohsten and colleagues, on the other hand, focused solely on cases of tamponade rather than perforation per se (7). They identified 15 cases of tamponade occurring in 6999 coronary interventions (0. Nevertheless, it is clear that coronary perforation is a rare complication, seldom amounting to more than 1% of all cases performed. A consistent finding in all of these publications is that the development of tamponade in the context of coronary perforation imparts a very poor prognosis. Of 31 cases of tamponade, 14 presented more than 4 h after the interventional procedure. The mortality in these late presenters was lower than those who had a more precipitous course within the catheter laboratory (21% versus 59%), but it was still appreciable. Furthermore, even on retrospective analysis of the cases, it was not possible to identify the bleeding point leading to tamponade in 10 of the 14 late presenters. This would suggest that the likely mechanism was distal branch perforation from the guide wire. In a report by Javaid and colleagues in 2006, 11 of the 14 cases of tamponade (79%) died (18). In our study the mortality of the 24 patients who developed tamponade following perforation was 25%, even though half of these cases underwent emergency surgery prior to demise. Five of the 24 instances of tamponade presented more than 2 h after the procedure, but fortunately all of these survived. All five were related to distal wire perforation and four of the five procedures had involved coadministration of abciximab. Late onset and late identification of a pericardial collection is reported in a number of the other studies (1, 6, 7, 11, 29). Nine of the ten cases of delayed tamponade occurred in the first 5 h after completion of procedure. Again, these cases of delayed tamponade were presumably due to distal wire perforations. A high level of awareness should be maintained for the possible development of this late manifestation, even if perforation is not immediately obvious on angiography. The clinical picture may be rather non-specific, and the patient may simply develop progressive hypotension. There are a number of other plausible explanations for a fall in blood pressure following intervention, such as a vagal response to sheath removal, so suspicion should be maintained to secure the correct diagnosis in a timely fashion. Although tamponade imposes a poor outlook, low-grade perforations usually fare well with conservative management. Fukutomi and colleagues reported excellent outcomes in 51 cases with type I perforation (11). Similarly, Javaid and colleagues found that all 14 cases of type I perforation in their series enjoyed an uneventful recovery, although one patient with very severe multivessel disease went forward for early bypass surgery (18). It is intuitive therefore that the angiographic appearance of the coronary perforation has some bearing on the ultimate outcome. Furthermore, the outlook is worse if tamponade develops abruptly within the catheter laboratory, rather than in a delayed fashion on the ward (10). From these results it is clear that those cases who have the most precipitous haemodynamic deterioration do worst. The bigger the vessel rupture, the more rapid the bleed into the pericardial space. Javaid and colleagues found that the presence of chronic renal dysfunction had a deleterious influence on mortality (18). It is also likely that pre-procedural impairment of left ventricular function confers a worse outlook but this is less clear from the available data. Stankovic and colleagues observed the changing pattern of coronary perforation over a 9-year period within their institution in Milan, Italy (16). This included a very significant fall in the requirement for emergency coronary bypass and/or subsequent death (31. Favourable outcomes are reported by most authors without the need for recourse to surgery (1, 13). Furthermore, this type of perforation constitutes a very small minority of those reported. It would be reasonable to assume that treatment of a discreet, short lesion in the mid-segment of a 3-mm vessel, without undue tortuosity or calcification, should present a low risk of perforation. Logically, therefore, the antithesis of this description represents the vessel at most risk of rupture or perforation. Although calcification may develop early on in the process of atherosclerosis, it is usually a feature of long-standing coronary disease. Calcification of the intima presents a technical challenge for the interventionalist. Unlike a more forgiving elastic vessel, the calcified artery may initially be very resistant to balloon preparation, but will abruptly capitulate, often by dissecting or tearing. Intimal calcification is best dealt with by lesion preparation (debulking) prior to stenting. Rotational atherectomy is the most widely used technique for this purpose, and in some institutions excimer laser is employed. These findings are in keeping with the results of other published series (10, 12, 13, 24, 26). This reinforces the point that the substrate (calcification) rather than the treatment modality augments the risk of perforation. Dealing with these vessels by balloon and stent alone is just as likely to result in this complication, if not more so than when using designated technology. Tortuosity is another well-recognized risk factor and is identified as characterizing between 39% and 46% of perforated coronary arteries (8, 10, 13, 18). A number of authors have also concluded that eccentric lesions are more likely to rupture (10, 16, 31). This ties in with most of the other series (8, 13, 18), with the exception of Eggebrecht and colleagues, who noted that 12 of 19 cases of perforation occurred when attempting to open a chronically occluded vessel (14). There has been some debate as to whether coronary lumen size clearly predicts likelihood of problems. Nevertheless, in the series reported by Javaid and colleagues just over 40% of perforation was seen in vessels of less than 2. These authors describe that device/lumen mismatch is more important than the vessel reference diameter. Ajluni and colleagues observed that balloon-induced perforation was more likely where the balloon to artery ratio was 1. Ellis and colleagues recorded similar findings where lesions complicated by perforation had a ratio of 1. Almost all studies report the mean age of the perforation cohort to be in the mid 60s. The only authors to demonstrate that this age was significantly higher than the group who did not perforate were Ellis and colleagues (1). The heparin doses administered at that time were considerably higher than those currently used to meet the requirements for intracoronary stents. There is now a greater emphasis on platelet inhibition rather than anticoagulation. In current practice, the primary role of heparin is to avert thrombus formation on equipment (guide wires, balloons, and catheters) during the procedure. Reversal of the effects of unfractionated heparin by the administration of protamine is well documented as a first-line strategy when coronary perforation occurs. This has been shown to be of value, particularly in lower grade perforations (11, 13, 19). The vast majority of coronary intervention now involves the dual antiplatelet therapy of aspirin combined with either clopidogrel, prasugrel, or ticagrelor. This is, perhaps, a situation where interventional cardiology demands the art of medicine rather than the science. Abciximab binds irreversibly to platelet receptors, rendering platelet activity almost negligible for 24­36 h. If coronary perforation occurs when these drugs have been administered, establishing control of the bleeding may prove difficult. Dippel and colleagues examined the records of 6214 interventions between 1995 and 1999, complicated by 36 perforations (9). While proportionate use of this agent increased steadily over the 5 years analysed, there was no increase in the incidence of perforation or tamponade. These authors concluded that it was the angiographic appearance of the perforation that predicted an adverse clinical outcome rather than the use of these drugs. However, in their article they did not determine whether those receiving abciximab fared better or worse than those who had not. They simply examined the temporal relationship of complications to the increased use of abciximab. Fasseas and colleagues compared 33 perforations where these agents had been administered, with 62 cases without administration (13). Others report a negligible influence associated with the use of these agents (11, 15). However, in our study with colleagues in 2002, we reported some changes in the pattern seen (12). Confining attention solely to those cases of perforation that culminated in tamponade, we observed an increased overall incidence of tamponade for the years analysed (1995­2001) that corresponded with the increased abciximab usage in our unit. Furthermore, the proportion of such cases of tamponade where abciximab administration was associated increased from 17% in 1999 to 86% in 2001. It is important to note that in 40% of instances of tamponade where abciximab had been administered, it only became manifest more than 2 h after the procedure. Retrospective analysis of the angiograms in these cases revealed little or no evidence of extravasation. Where it was identified, the mechanism was clearly wire-tip trauma to a distal subbranch. Therefore, unlike the smaller molecules tirofiban and integrilin, simply discontinuing the infusion of abciximab will not reverse these effects. Platelet transfusion is of value in correcting the bleeding time and this has been clearly demonstrated (32). However, administering platelets goes somewhat against the objective of maintaining stent patency by inhibiting this arm of the clotting process. Therefore a number of authors recommend either avoiding a transfusion where feasible or even continuing abciximab in the most complex cases (33). However, the point has been made earlier that the increased complication rate using these devices is strongly influenced by the complexity of the coronary disease being treated. Ellis and colleagues were the first to highlight the potential problems with new devices in their report of 1994 (1). The incidence of perforation with balloon angioplasty was a mere 14 out of 9080 cases (0. Therefore experience with all of the debulking techniques was still developing at this time. The excimer laser registry results published in 1993 identified perforation in 23 out of 764 patients (3%) (34). While no patients died, nine of the 23 suffered a significant haemodynamic insult from this. The authors concluded that down-sizing the laser catheter, rendering the device at least l mm smaller than the reference artery diameter, reduced the risk of perforation. This advice must have been heeded as the subsequent registry report on excimer laser the following year by Holmes and colleagues indicated an improvement, with 36 of 2759 (1. The authors specifically commented on the reduction in complication rates as operators became more experienced, with laser perforations declining from 1. This involves the use of a rapidly rotating drill tipped with industrial diamond over a fine monofilament steel wire. Very little has changed in the equipment employed for this procedure in the 35 years that have elapsed since its inception. Reisman and colleagues described the outcome in two chronological registries, one between 1988 and 1993 and the other from 1994 to 1997 (36). The results reported by Von Sohsten and colleagues highlighted an important issue; while they identified tamponade in eight of 743 rotablator procedures, seven of these eight instances were actually as a consequence of a temporary pacing wire puncturing the right ventricle, rather than coronary perforation per se (7). Softer, smaller calibre pacing wires are now available, which are much less likely to produce this problem. However, rotablation itself was not directly responsible for perforation in any patient in this series. In the three cases in which rotablation was used, perforation occurred during stent deployment in two cases and during cutting balloon inflation in the other. Across the nation in 2014, 2334 rotablation procedures were performed, which is part of a continuing pattern of increased uptake (30).

Water: the desirable water content of the gelatin solution used to produce a soft gelatin capsule shell depends on the viscosity of the specific grade of gelatin used nerve pain treatment back buy generic rizatriptan 10 mg online. Preservative: Preservatives are often added to prevent the growth of bacteria and mold in the gelatin solution during storage knee pain treatment by physiotherapy cheap rizatriptan master card. Potassium sorbate backbone pain treatment yoga rizatriptan 10 mg for sale, and methyl pain treatment for neuropathy order 10 mg rizatriptan overnight delivery, ethyl joint and pain treatment center fresno ca 10 mg rizatriptan overnight delivery, and propyl hydroxybenzoate are commonly used as preservatives. The color of the capsule shell is generally chosen to be darker than that of its contents. Other excipients: Other, infrequently, used excipients can include flavors and sweeteners to improve palatability and acid-resistant polymers to impart enteric release characteristics. For example, Accutane is a suspension of isotretinoin in oil, Sandimmune is a self-emulsifying preconcentrate, and Neoral is a self-microemulsifying preconcentrate. Formulation considerations for the contents of the soft gelatin capsules include the following: · Noninteraction with gelatin: the contents of the soft gelatin capsule should not interact with the gelatin shell. Therefore, to ensure chemical stability of the drug, moisture-sensitive drugs should not be formulated in soft gelatin capsules. Therefore, the sealing operation is usually carried out at a higher than ambient temperature. Hence, highly thermolabile drugs may not be encapsulated in soft gelatin capsules. Tanning process involves crosslinking of gelatin, which results in hardening of the shell. Drugs for encapsulation in a soft gelatin capsule are usually dissolved or suspended in a suitable carrier. Insoluble drugs are often dispersed or suspended in an agent such as beeswax, soybean oil, or paraffin. The use of water or ethanol in the fill composition is only possible with special modifications of the capsule shell. They are prepared from a more flexible plasticized gelatin by a rotary-die process. Two heated sheets of gelatin of similar thickness are produced by the controlled flow of the fluid gelatin from its heated storage container (gelatin tank) by using a controlled pore opening and fill in a spreader box. The gelatin film flows through a series of oil rolls that stretch the sheets and direct them appropriately toward die rollers. The two sheets of gelatin merge on the metallic rollers that contain dies of appropriate shape and size and move in the opposite direction toward each other. The application of vacuum inside the rollers combined with pressurized filling of the components enables the formation of a cavity. The application of heat and mechanical pressure enables sealing of the shells as they pass through the rollers. As the gelatin sheets are being annealed, a calibrated amount of the drug formulation is pumped into each cavity by the product pump through an injection wedge. The filled capsules are dried at ambient conditions to remove moisture from the outer surface and may be tray dried for an extended period of time. Finished capsules are passed on a conveyor belt for the next unit operations of packaging and labeling. These batteries of tests are carried out at predefined intervals during the product manufacturing, by the manufacturing personnel, and their results recorded on the batch record. Adverse findings in these tests can be used as a guide to alter the manufacturing-process parameters. These tests help identify whether the batch is acceptable for marketing or its intended usage. These tests are frequently carried out after defined periods of storage at predetermined conditions. During the encapsulation of soft gelatin capsules, the following parameters are usually closely monitored and controlled: · · · · · Gel ribbon thickness and uniformity across the ribbon Seal thickness Weight of the capsule fill and its variation from capsule-to-capsule Weight of the capsule shell and its variation from capsule-to-capsule Moisture level of the capsule shell before and after drying Visual inspection, fill weight, and fill-weight uniformity are the key inprocess tests used for hard gelatin capsules. Similarly, hard gelatin capsules are tested for any breach of physical integrity (breakage or opened cap and body). In addition, most drug products are tested for the related substances or impurities. The emptied shells are individually weighed and the net weight of the contents is calculated by subtraction. The content of active ingredient in each capsule may be determined by calculation based on the percent drug content in the formulation for high drug load formulations. For soft gelatin capsules, the gross weight of 10 gelatin capsules is determined individually. Then each capsule is cut open, and the contents are removed by washing with a suitable solvent (that dissolves the fill but not the shell). The solvent is allowed to evaporate at room temperature, followed by weighing of the individual washed shells. The net contents are calculated by subtraction and the content of active ingredient in each of the capsules can be determined by calculation based on the percent drug content in the formulation. Fill-weight variation of capsules is often a function of equipment setup and filling operation. An automated capsule sizing machine and/or weight checker is frequently used to discard over- or underfilled capsules. For low drug load and low fill-weight formulations, each capsule must be analyzed individually by the potency method for the content of the active ingredient. The uniformity of content is assured if predetermined criteria for the range and variation in the content of the active ingredient are met. The rate and extent of dissolution of the drug from the capsule dosage form is tested by a dissolution test. Dissolution test provides means Capsules 529 of quality control in ensuring that (a) different batches of the drug product have similar drug release characteristics and (b) that a given batch has similar dissolution as the batch of capsules that was shown initially to be clinically effective. These tests are usually carried out by incubation of the capsule contents in a growth medium and counting the colonies formed after a predefined period of time. Selection of the growth medium and duration of the test, as well as maintenance of aseptic conditions during the testing, are critical to successful assessment of microbial contamination by this method. Since the shelf life of the product at recommended storage conditions can be long, the product is often subjected to accelerated (higher than normal levels of environmental conditions) storage for predicting shelf life under recommended storage conditions. These storage conditions that are accelerated for stability testing include temperature, humidity, and light. The exact conditions for real-time and accelerated storage testing depend on the geographic and climatic region where the drug product is intended to be manufactured and marketed. Enlist the common parenteral routes of drug administration and discuss circumstances where one route may be preferred over another. Define sterilization and describe the methods of sterilization of injectable products. Most of the parenteral drug products are injectable dosage forms that are intended for administration by injection using a syringe and a needle. Parenteral dosage forms are preferred for one or more of the following reasons: · Low oral bioavailability and/or high variability in oral drug absorption. For example, emergency medications such as analgesics, anticancer drugs, and fertility medications. These include most protein and peptide drugs, some antibiotics, heparin, lidocaine, protamine, glucagon, and many anticancer compounds. Certain drugs, on the other hand, are available both as parenteral and oral dosage forms for different clinical settings. For example, analgesics and antihistamine drugs for patient self-administration may be available as oral tablets, whereas they are also available as infusions and injections for use in an emergency room or hospital settings where rapid onset of drug action may be desired. Similarly, hormonal drugs, such as progestins and antiprogestins, are available as tablets for use in contraception, and are also available as injectable dosage forms for use in fertility therapy. Nevertheless, drugs may be administered into almost any organs or area in the body, including the joints (intraarticular), joint fluid area (intrasynovial), spinal column (intraspinal), spinal fluid (intrathecal), arteries (intraarterial), and in the heart (intracardiac). In addition, parenteral routes of administration include dosage forms such as sublingual tablets, transdermal patches, and inhalers-which will not be discussed in this chapter. An infusion refers to the introduction of larger volumes (100­1000 mL) of the drug over a longer period of time. A continuous infusion is used to administer a large volume of drug at a constant rate. Intermittent infusions are used to administer a relatively small volume of drug over a specified amount of time at specified intervals. Other solutions of essential amino acids or lipid emulsions are also used as infusions. Aqueous or oleaginous solutions or suspensions of drugs may be administered intramuscularly. Drugs in aqueous solution are absorbed more rapidly than those in oleaginous preparations or in suspensions. Up to 2 mL of the drug may be injected into the upper arm and 5 mL in the gluteal medial muscle of each buttock. Numerous dosage forms are administered through this route of administration, including solutions (aqueous- or oil-based), emulsions (o/w or w/o), suspensions (aqueous- or oil-based), colloidal suspensions, and reconstitutable powders. Drugs often given by this route include epinephrine, insulin, heparin, scopolamine, and vaccines. Small injection volume often puts limitations on the drugs that can be administered by this route. For example, high dose drugs that tend to become highly viscous at high concentrations, such as most globular proteins, are usually difficult to formulate as subcutaneous injectable dosage forms. For example, · Intradermal administration involves injection just beneath the epidermis, within the dermal or skin layers. The onset of action and the rate of absorption of medication from this route are slow. This route is used for diagnostic agents, desensitization, testing for potential allergies, or immunization. Drugs administered intrathecally include antineoplastics, antibiotics, anti-inflammatory, and diagnostic agents. For example, an intraarticular injection of a corticosteroid provides an anti-inflammatory action in an arthritic joint. For example, an injection into the vitreous humor provides access of drug to the rear regions of the eye, such as the retina, which does not receive high drug concentration on topical administration. Drugs injected intravenously are immediately available in the systemic circulation. The rate of drug absorption from the site of administration to the systemic circulation depends on the blood flow to the site and drug diffusivity in the tissue. The extent of drug absorption from a parenteral route could be lower if the drug is metabolized in the tissues. In certain cases, formulation of low volume injections is not feasible, especially for protein drugs with high doses. Unit dose containers are usually hermetically sealed ampoules that are intended to be discarded after a single injection. Multidose containers, on the other hand, are usually rubber-stoppered and sealed glass vials that are intended for multiple injections. The drug for each injection is withdrawn by inserting the needle through the rubber stopper, which self-seals after the needle is withdrawn. Infusions are commonly used for fluid replacement, administration of drugs with a short plasma half-life, and/or dilution of a drug immediately before administration. Solutions that do not contain any antimicrobial agents should be terminally sterilized. Autoclaving is the preferred method for terminal sterilization whenever drug solutions can withstand heat. To achieve these properties, it is necessary to select and carefully maintain particle size distribution, zeta potential, rheological properties, and wettability. Injectable suspensions often consist of the active ingredient suspended in an aqueous vehicle containing an antimicrobial preservative, a surfactant, a suspending agent, a buffer, and/or a salt. Due to the inherent long-term physical instability of suspensions, parenteral suspension dosage forms are formulated as dry powders for reconstitution immediately before administration. The sterile dry powder could be produced by freeze-drying, sterile crystallization, or by spray-drying. Parenteral suspensions are prepared by mixing dry powders in sterile vehicles immediately before administration. Lyophilization or freeze-drying is used to prepare powder cakes for reconstitution immediately before administration. It has inherent advantages over other methods of preparation of dry powders, such as · Water is removed at low temperatures, avoiding damage to heatsensitive drugs. Thus, it does not require powder filling, which is technologically more challenging than filling solutions. Despite the advantages of freeze-drying, cautions must be taken for lyophilizing proteins, liposomal systems, and vaccines, because they tend to get damaged by freezing, freeze-drying, or both. These damages can often be minimized by using protective agents, such as polyols, polysaccharides, disaccharides and monosaccharide. Injectable products are usually required to be tested for the following characteristics: 22. Such conducive environment includes appropriate temperature, humidity, and nutrient media. Microbial growth is monitored after a given period of time, determined by standard protocols for each type of microbes. There are two methods of sterility testing: · Direct inoculation: the drug product is added to the nutrient media and incubated, followed by observation for any microbial growth.

After granulation treatment pain behind knee generic rizatriptan 10 mg, when the granulating fluid is dried off active pain treatment knoxville tn rizatriptan 10 mg amex, the particles tend to continue to adhere in relatively strong agglomerates through multiple blue sky pain treatment center/health services rizatriptan 10 mg otc, weak noncovalent forces of adhesion among primary particles promoted by the hydrophilic polymer (binder) advanced pain treatment center union sc cheap rizatriptan 10 mg buy on line. These particles tend to have higher sphericity than primary particles and can be milled or sifted to the desired particle size distribution pain medication for a uti cheap rizatriptan 10 mg on-line. Thus, granulation enables flow and compressibility while modifying the surface properties of primary particles such as sticking to stainless steel equipment. These processes are typically direct compression processes that do not require separate granulation and drying unit operations. These hydrophilic polymers are called binders, when used for such purposes in these formulations. In wet granulation, the binder can either be dissolved in the granulating fluid or added dry to the powder mixture followed by the addition of the granulating fluid for wet granulation. The type and concentration 496 Pharmaceutical Dosage Forms and Drug Delivery of binder affect the granule strength, friability, and the granule growth rate during the wet-granulation process. These glidants are very small size powder particles that occupy surface ridges and irregularities in coarse powder particles, thus increasing the sphericity and reducing the tendency to adhere to surfaces. Thus, lubricants reduce or prevent adhesion of powder particles to tablet compression punch faces and dies or to the rolls of a roller compactor. They promote flow, reduce interparticle friction, and facilitate the smooth ejection of compressed tablets from the die cavity. Commonly used lubricants are magnesium stearate, stearic acid, and sodium stearyl fumarate. These lubricants are small hydrophobic particles that tend to coat the surface of larger powder particles by spreading out under the mild shear during mixing. Hydrophobic surface coating reduces noncovalent hydrophilic interparticle and particleequipment forces that are generally responsible for adhesion and sticking. The lubricity of magnesium stearate in a formulation can be increased with either the concentration or the duration of mixing. Overlubrication, due to the use of high concentration or excessive mixing can result in reduced compactibility of the blend and/or rate of drug release from the tablets. Sodium stearyl fumarate is the only water soluble or hydrophilic lubricant and is used in formulations that are highly sensitive to hydrophobic lubricants. Disintegrants help break a compressed tablet into constituent granules and primary powder particles. Thus, breaking of the tablets by disintegrants increases the effective surface area and promotes rapid release and dissolution of the drug. Disintegrants act by either or both (a) swelling in the presence of water and bursting tablet and granule open and/or (b) capillary action to promote rapid ingress of water into the center of the tablet or capsule. Long open chains of hydrophilic polymers can serve as a binder by promoting hydrogen bonding and hydrophilic bonding forces on the surface of powder particles. When these polymer chains are cross-linked, they can imbibe water and swell due to their high hydrogen bonding capacity-thus acting as a disintegrant. Artificial sweeteners, such as acesulfame potassium and saccharin sodium, are preferred because smaller quantities produce similar or higher sweetness than sucrose. Several punches and dies are arranged on three rotary turrets on a high-speed rotary tablet press that move concurrently in a circular motion as the tablets are made. This process requires · Uniform flow of blend into the die cavity through a hopper and feedframe. Inadequate powder flow can lead to variable die filling, which produces tablets that vary in weight, drug content, and strength (hardness). Therefore, steps must be taken to ensure that the proper powder flow is maintained. Incorporation of a glidant and/or a lubricant Tablets 499 into the formulation enhances the powder flow. Processes such as spray drying, fluid-bed granulation or extrusion spheronization increase the sphericity of granules. In addition, increasing the density of granules, such as by granulation, also improves the powder flow. The most popular method of increasing the flow properties of powder is by granulation. As discussed earlier, granulation could be either dry granulation, which does not use a granulating fluid, or wet granulation, which involves wetting with a fluid followed by drying. Compressibility is the property of forming a stable, intact compact mass when pressure is applied. Compressibility is an outcome of the extent of plastic deformation that a material can undergo combined with cohesive forces among the powder blend that will keep the material in the compressed state. Most materials exhibit different degrees of elastic recovery, that is, expansion toward original higher volume on removal of stress. Low elastic recoveries coupled with high plastic deformability and high interparticle adhesion promote the formation of strong compacts at low compression forces. Direct compression: Direct compression is the preferred method if powder blend has adequate flow, compactibility, and cohesion with low segregation potential. Direct compression involves simply mixing the required ingredients and compressing them into tablets on the press. Dry granulation: Dry granulation is preferred in circumstances where powder flow, cohesion, and/or segregation potential need to be improved, but compactibility is adequate. It can be carried out by either of two processes: (a) slugging, which involves compression using large punches and dies in a tablet press; or (b) roller compaction, which involves forcing the powder blend between two counterrotating rolls that are pressed together under hydraulic pressure. These granules are then mixed with extragranular excipients and compressed on the tablet press. Wet granulation: Wet granulation is preferred when compactibility of the powder is not very high and there is a need to improve the flow, cohesion, and/or segregation potential of the powder blend. The use of nonaqueous granulation liquids, such as ethanol, is no longer preferred for safety and environmental reasons. The formed granules are dried in a tray or fluid bed dryer at moderately elevated temperatures. Dried granules are then mixed with extragranular excipients and compressed on the tablet press. Low or high-shear wet granulation: Depending on the design of the granulator, wet granulation could impart low or high levels of shear to the powder blend and are termed accordingly. Low-shear granulation generally yields higher porosity, higher compactibility, and lower density of the formed granules. A choice between low- and high-shear granulation is based on the sensitivity of the desired product quality attributes to process conditions. Fluid-bed granulation: Fluid-bed granulation involves the spray of the granulating liquid on the fluidized powder bed. This process 502 Pharmaceutical Dosage Forms and Drug Delivery combines the drying step with the granulation step. In this process, the evaporation of the granulating liquid is concurrent with the granulation of the powder blend. It is a relatively slow, but a well-controlled process that leads to the generation of granules, which are more porous, less dense, and more uniform in shape and size. Moisture-activated dry granulation: Other processes commonly employed for preparing powder blend for compression involve a combination of the three basic processes. Continuous granulation: Use a continuous granulation process minimizes the material transfers and enables flexibility of batch size. Continuous processes are based on a tunnel or channel of powder flow with sequential positions where different steps of a process-such as water addition, drying, and milling in the case of wet granulation- are carried out in tandem. Products that are prone to decomposition by moisture generally are copackaged with desiccants, such as silicon dioxide. Drugs that are adversely affected by light are packaged in light-resistant containers. The general appearance of the tablet allows monitoring a lotto-lot and tablet-to-tablet uniformity. Tight control of tablet thickness is required to ensure automated machine operations during its packaging and handling. Tablet-to-tablet thickness within a batch and average thickness of tablets across all batches are defined and controlled. This is usually tested by an analytical method for drug potency (such as highperformance liquid chromatography) in a several individual tablets. It is representative of the tensile strength of a tablet and is determined by the cohesion characteristics of the powder blend. If tablets are too hard, they may not disintegrate within a reasonable period of time. This can lead to reduced bioavailability and failure to meet the dissolution specification. If they are too soft, then they may not withstand the handling and shipping operations, leading to tablet breakage or chipping (breaking away from edges) and failure during friability testing. It is a function of the fragility of the compressed powder blend, tablet shape, cohesion, and hardness. Low tablet friability is desired to ensure its physical integrity during packaging, shipment, and handling. Under the assumption of normality of statistical distribution of tablet weight, all tablets are required to be within a certain range of the predefined tablet weight. Several tablets are weighed individually, and both the average weight and variation of individual tablet weight from the average are calculated and controlled during the manufacturing to ensure that the tablets contain the desired amounts of drug substances, with no more than acceptable variation among tablets within a batch. Tablet disintegration is evaluated in a standardized apparatus that subjects six tablets to a defined mechanical stress in individual reciprocating cylinders in a suitable aqueous medium at 37°C, to reflect the conditions on oral ingestion. The time it takes for the last of six tablets to disintegrate into smaller particles and disappear from the reciprocating cylinders is called disintegration time. The disintegration media required varies depending on the type of tablets to be tested. The rate and extent of dissolution of a drug are tested in vitro by a suitable dissolution test. Dissolution test provides a means of control in ensuring that a given tablet formulation is similar with respect to the rate and extent of drug release as the batch of tablets were shown initially to be clinically effective. Excipients for tablet formulation affect the rates of disintegration, dissolution, and absorption. Tablet disintegration, dissolution, and drug absorption are influenced by physicochemical properties. In these processes, the rate at which drug reaches the circulatory system is determined by the slowest step in the sequence. Disintegration of a tablet is usually more rapid than drug dissolution and absorption. For the drug that has poor aqueous solubility, the rate at which the drug dissolves (dissolution) is often the slowest step, and therefore exerts a rate-limiting effect on drug bioavailability. In contrast, for the drug that has a high aqueous solubility, the dissolution rate is rapid and the rate at which the drug crosses or permeates cell membranes is the slowest or rate-limiting step. This classification system has been used to understand and influence (by formulation design) the oral pharmacokinetics of drugs. Lubricants prevent adherence of granules to the punch faces of the tableting machine C. You have recently faced the problem of tablet sticking to the punches during the tablet compression operation. Explain what modification in the formulation would be the easiest way to solve the problem B. You desire to formulate a highly insoluble compound into an oral pharmaceutical formulation. The formulation you prepared has excellent disintegration characteristics but the dissolution profile in water or acid media is very low (less than 10% dissolved in 60 minutes). You desire to redesign the dissolution conditions so as to achieve higher dissolution rates. Describe the types of formulations that are used in hard versus soft gelatin capsules. Identify cases in which the use of hard or soft gelatin capsules may be preferred over tablets. Depending on the composition of the gelatin shell, the capsules can be hard or soft gelatin capsules. Soft gelatin capsules (also known as softgels) are made from a relatively more flexible, plasticized gelatin film than hard gelatin capsules. Some soft gelatin capsules are intended for rectal or vaginal insertion as suppositories. Some soft gelatin capsules are intended to be cut open by the patient to remove and externally apply the contained medicament, for 509 510 Pharmaceutical Dosage Forms and Drug Delivery Round 0. These capsules are generally not physically stable in low humidity conditions, such as in the presence of desiccant in the packaged drug product. It is produced by irreversible, partial hydrolysis of collagen, which is obtained from animal skin and bones. It forms a semisolid colloid gel in the presence of water, which displays a temperature-dependent gel­sol transformation and viscoelastic flow. It has crystallites (microscopic crystals formed during the cooling phase of manufacture of capsule shells) that stabilize the three-dimensional gel network structure and are responsible for streaming birefringence in gelatin solutions. During the capsule filling unit operation, the body is filled with the medicament, followed by the insertion of the cap over the body. The larger, narrower part of the capsules is the body and the smaller, wider part is the cap. To meet this objective, capsules with the cap that covers most of the body were developed.

Radiolabeled cell distribution after intramyocardial pain medication for dogs dosage best 10 mg rizatriptan, intracoronary pain treatment for lumbar arthritis rizatriptan 10 mg buy otc, and interstitial retrograde coronary venous delivery: implications for current clinical trials georgia pain treatment center canton buy rizatriptan 10 mg with mastercard. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review pain treatment center winnipeg buy rizatriptan 10 mg with amex. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery regional pain treatment medical center rizatriptan 10 mg purchase fast delivery. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Assessing myocardial viability and infarct transmurality with left ventricular electromechanical mapping in patients with stable coronary artery disease: validation by delayed-enhancement magnetic resonance imaging. Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients. Identification of myocardial and vascular precursor cells in human and mouse epicardium. Preservation of left ventricular function and attenuation of remodeling after transplantation of human epicardium-derived cells into the infarcted mouse heart. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Safety of intramyocardial injection of autologous bone marrow cells to treat myocardial ischemia in pigs. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Biodegradable magnetic stent for coronary artery luminal regeneration (Biomagscar). Impaired myocardium regeneration with skeletal cell sheets-a preclinical trial for tissueengineered regeneration therapy. Spatially oriented, temporally sequential smooth muscle cell-endothelial progenitor cell bi-level cell sheet neovascularizes ischemic myocardium. Improvement of cardiac stem cell sheet therapy for chronic ischemic injury by adding endothelial progenitor cell transplantation: analysis of layer-specific regional cardiac function. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Autologous transplantation of bone marrow mononuclear stem cells by mini-thoracotomy in dilated cardiomyopathy: technique and early results. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Identify the objectives and key deliverables of the three stages of clinical trials. On average, it costs a company more than $1 billion and 10­15 years to get one drug from the laboratory to patients. Only five in ~5000 compounds that enter preclinical testing make it to human testing. Only one of those five drugs entering human clinical trials is approved for commercialization. A typical drug discovery process entails target identification, such as a protein or an enzyme whose inhibition may help in a disease state. The structural features necessary in a potential drug candidate are identified using in silico molecular modeling. Several drugs may be synthesized using combinatorial chemistry and screened for in vitro activity in high-throughput assays. The lead candidates are then synthesized in larger quantities, screened for biological activity, and further optimized to maximize the affinity, specificity, and potency. A highly specific compound that only binds the target site is likely to have minimal nontarget effects, which often lead to adverse effects and toxicity related to the mechanism of drug action. Drug development studies include preclinical studies, whereby a compound is thoroughly characterized for physicochemical characteristics and is tested in animal models for toxicity and activity. Stages of drug development that precede human testing are termed preclinical development, while human testing stage of a drug is termed clinical development. Clinical evidence of safety and efficacy of drug products forms the cornerstone of regulatory approval of any new drug product. Pharmaceutical development proceeds concurrent with clinical development and with the objectives of supporting the ongoing clinical studies (providing information, documentation, and the drug product for administration to the subjects) and preparation for commercialization of the product. Several activities on the drug product continue after commercialization, such as adverse event monitoring, development of line extension products, and additional clinical trials to support label claims or expand target patient populations. Discovery and preclinical testing to identify a lead compound and its detailed characterization for toxicity and bioactivity in vitro and in vivo can take a few years, such as about 3­4 years. A significant amount of time is taken by different phases of clinical trials, about 7­8 years, with increasing duration of time and number of patients required for higher stages of clinical trials. A typical mediumto large-sized biopharmaceutical company has several pipeline candidates that are at various stages of development. Pharmaceutical development follows a parallel track with preclinical and clinical development. Pharmaceutical development is responsible for chemistry, manufacturing, and control of both the drug substance and the drug product throughout the life cycle of a compound. This function provides a robust dosage form that meets three key requirements of a drug product: (a) stability, (b) bioavailability, and (c) manufacturability. The key roles of pharmaceutical development are to provide a suitable drug product in a stage-appropriate manner while also ensuring path to future development and commercialization and to bridge the drug product used during different stages of development. The progression of new drug candidates through various stages of this sequential process depends on successful demonstration of drug-like characteristics in each of these phases. Scientists working in a wide array of disciplines are responsible for both characterization and enablement of drug-like properties in new drug candidates throughout these stages of drug development. These stages are bounded by distinct boundaries, where the governance leadership of an organization must make a decision whether to continue to invest in a molecule or not. The preclinical stage includes detailed physicochemical characterization of the compound and animal studies. This stage has the objectives of identifying developability and clinical risks to the compound and of identifying a viable development path to a commercial drug product. In addition, a critical decision of the starting human dose is made based on the animal studies carried out during the preclinical phase. Prototype formulations are designed for use in animal efficacy studies, toxicological assessment, and phase I clinical studies. The ability to produce a commercially viable dosage form of the compound is assessed at this stage. Following identification of some lead compounds, the pharmacological and toxicological effects of these compounds are determined. These tests involve the use of laboratory animals, cell culture, enzymes, and receptors, as well as computer models. Animal testing may be carried out, for example, in transgenic mice or other animals, that exhibit the pharmacology of a particular disease state and/or drug target that defines the target patient population. These toxicology studies are intended to assess the organs or organ systems in which a particular compound tends to exhibit toxicity as well as to identify the doses at which the toxicity appears. These animal studies are used to understand how the drug is absorbed, distributed, and metabolized in the body; ascertain its metabolites; and determine how quickly the drug is excreted from the body. Interspecies dose scaling for small-molecule compounds is generally carried out using body weight as a metric, for example, mg dose per kg body weight is kept constant across species. The metric for biologic compounds, for example, therapeutic proteins and antibodies, is generally dose per unit body surface area. Such division, through distinct clinical protocols, is intended to utilize the results of the previous phase or subphase of the study to inform the design of the next phase of the study. Phase I clinical studies are aimed at identifying dose-limiting toxicities, toxicological profile, dose­exposure relationship, and drug pharmacokinetics in a small group of healthy or patient volunteers. The drug is administered at very low doses, based on the observations in animal studies. Phase I studies are typically carried out in healthy volunteers to assess toxicity and define doses for human administration. For example, studies with cytotoxic anticancer drugs are not carried out in healthy volunteers, and placebo may not be used as a comparator for patients with serious diseases. Increasingly, the demarcation between different phases of clinical development are getting blurred with the key defining criterion of clinical studies being restricted to nonregistrational dose-escalation studies and registrational studies. Examples of other focused studies include food effect evaluation, drug­drug interaction studies, and studies in special populations such as in renally compromised patients. As clinical trials progress, the dose and dosing regimen are optimized to the effective levels that present an acceptable toxicologic profile. In addition to the characterization of the clinical profile of the drug candidate (such as the dose and frequency of administration), these studies seek to differentiate the new drug candidate from the existing therapeutic options for a given set of patients. In addition, studies may be carried out in special patient populations-such as pediatrics, geriatrics, and renally compromised patients-to more closely define the dosage and risk­benefit profile in those patient populations. These studies are closely monitored and may be conducted in patients (when ethically required. Phase I clinical trials are relatively short (several months) and involve relatively less number of human volunteers (6­20). The purpose of a phase I clinical trial is to establish the tolerance of the drug in healthy human subjects at different doses and define its pharmacologic effects. The purpose of a phase I clinical trial is to establish a safe dosage range by determining the tolerance of the drug in healthy human subjects at different doses and define its pharmacological effects. Information about the pharmacokinetic profiles of the drug in humans is used to design appropriate dosing regimens for the next phase of clinical trials. This phase of testing also helps determine the common short-term side effects and risks associated with the drug. Two key aspects of late-stage clinical development are (1) randomization, and (2) blinding. Placement of the subject into the drug treatment or control group is done by random assignment. The randomization of subject assignment is an important statistical control to obviate any bias in study design. Such a clinical study in which the patient does not know the therapy but the healthcare providers, including the physician, may know what is being administered is called a single-blind study. The drug product manufacturer often carries out double blinding by providing two look-alike medicinal products that are only coded differently. In certain cases, the blinding may be carried out by the on-site healthcare professional, such as the pharmacist, who prepares drug products for administration and prepares the blinded labels. This phase usually lasts several years and involves approximately 500­3,000 patients in clinics and hospitals. Physicians monitor patients closely to determine efficacy and identify adverse reactions. Such decisions are made on a case-by-case basis, depending on the exact disease area and the therapeutic profile of the investigational drug candidate. As mentioned earlier, the division of clinical studies into distinct phases is based on the generation of distinct clinical protocols, with an intention to utilize the results of the previous phase or subphase of the study to inform Drug development 35 the design of the next phase of the study.

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label back pain treatment ucla rizatriptan 10 mg purchase amex, randomised shalom pain treatment medical center purchase rizatriptan with a visa, controlled trial treatment guidelines for neck pain 10 mg rizatriptan order fast delivery. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates pain treatment back buy rizatriptan 10 mg with amex. Clopidogrel for coronary stenting: response variability phantom pain treatment rizatriptan 10 mg with visa, drug resistance, and the effect of pretreatment platelet reactivity. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Gender and responses to aspirin and clopidogrel: insights using short thrombelastography. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. Prognostic significance of post-clopidogrel platelet reactivity assessed by point-of-care assay on thrombotic events after drug-eluting stents. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. Adenosine diphosphateinduced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in chinese patients undergoing coronary stenting with clopidogrel. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Relationship between posttreatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and metaanalysis. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Vasospasm derived from underlying endothelial dysfunction in the atheromatous vessel wall together with local and systemic catecholamine release causes vasoconstriction and can impair flow further (12). Fibrinolysis can also have prothrombotic effects in the absence of antiplatelet agents and systemic anticoagulation by releasing thrombin that had been bound within the fibrin clot. A huge amount of research and development has therefore been directed to finding therapies to attenuate these deleterious effects. The pathophysiology of plaque rupture Acute coronary syndromes There is a wide variety of atheromatous lesion types found within the coronary arteries, and these are defined both by their histological and associated clinical features (5). Progression in plaque development is accelerated by conditions such as hypertension, diabetes mellitus, hypercholesterolaemia, and smoking. Rupture of the fibrous cap exposes the highly thrombogenic material contained within the plaque to the circulating blood (7). It was found from initial studies that >80% receptor occupancy was considered optimal to maximize the benefits of these agents (24). The apparent lack of consistency seen in the results from the large number of clinical trials examining the effects of these different agents possibly reflects the heterogeneity in the levels of inhibition obtained (25). Following plaque rupture, platelets are activated by coming into contact with the newly exposed subendothelium. The drug is administered intravenously at an initial bolus dose of 250 g/kg body weight followed by a maintenance dose of 0. It is a large molecule and its strong binding results in a prolonged period of platelet inhibition that may last for up to 48 h after the drug has been discontinued. This makes any reversal of the potent antiplatelet effect of abciximab difficult and can have important clinical implications. It is dissipated slowly by being transferred to unoccupied receptor sites on other platelets, gradually reducing the antiplatelet effect and eventually undergoing protease degradation (28). If rapid reversal of action is required then platelet transfusion is effective in speeding this process. Although the significance of this is unclear there is concern that this may predispose to immune-mediated hypersensitivity reactions and profound thrombocytopaenia on subsequent readministrations of the drug. The prevalence of severe and profound thrombocytopaenia in patients who were readministered abciximab (2. This, and the simultaneous formation of a fibrin mesh (not shown), lead to the formation of a platelet thrombus. They exhibit differing pharmacokinetics to abciximab by binding the receptor with low affinity but in a much more specific and dose-dependent manner. This competitive and highly reversible mode of action results in a large proportion of the drug freely circulating in the plasma during steady state. Eptifibatide is a cyclic heptapeptide small molecule and is administered intravenously with an initial bolus dose of 180 g/kg body weight followed by a maintenance dose of 2. Tirofiban is a non-peptide tyrosine derivative and is administered intravenously at an initial dose of 0. Both eptifibatide and tirofiban exhibit first-order kinetics and are predominantly renally excreted. They have a short action of platelet inhibition compared to abciximab (eptifibatide 2­4 h; tirofiban 4­8 h). In the case of the need for rapid reversal, platelet transfusion is of little benefit as a large proportion of the drug is non-receptor-bound and the receptor sites on the new platelets are simply bound by the freely circulating drug (Table 25. Over 15,000 patients have been studied in several large randomized trials (see Table 25. All three agents have been evaluated in this setting, although abciximab has been studied the most thoroughly. The original trials in the mid-1990s had low rates of stenting, almost universal femoral vascular access, no oral thienopyridine loading, and high rates of periprocedural ischaemic and vascular complications. Although it is very useful to look back at these early trials, they must be examined in the context of the era in which they were carried out. The trial was terminated at the first interim analysis, with 2792 of the planned 4800 patients enrolled. There were no significant differences among the groups in the risk of major bleeding, Table 25. Patients were assigned one of three treatments: placebo (n = 1328), a bolus of 135 g/kg eptifibatide followed by an infusion of 0. The coronary procedure was started within 10­60 min of the start of study treatment. The benefit of eptifibatide was sustained, still being present at 6 months and 1 year (40, 41). The effect was particularly noted in diabetic patients who were also obese and hypertensive and in those patients with diabetes undergoing multivessel disease (33). No improvement was found in the abciximab group, possibly because of the beneficial effect of the clopidogrel. The study, however, may have been underpowered to demonstrate a benefit of abciximab in such a patient group. In select patients, however, with complex lesions and an unstable periprocedural course abciximab may be useful (36). A small, single-centre study involving 93 patients served as a dose-ranging and safety study (43). The relative benefit of abciximab was consistent regardless of age, sex, the presence or absence of diabetes, or the presence or absence of pretreatment with clopidogrel. There were no significant differences in the rates of major bleeding complications or transfusions, but tirofiban was associated with a lower rate of minor bleeding episodes and thrombocytopaenia. It was suggested that an insufficient dosing regime and patients failing to reach adequate levels of platelet inhibition perhaps attenuated the clinical benefit of tirofiban in this study. Level of evidence A: Data derived from multiple randomized clinical trials or meta-analyses; Level of evidence B: Data derived from a single randomized clinical trial or large non-randomized studies; Level of evidence C: Consensus of opinion of the experts and/or small studies, retrospective studies, registries. By 6 months, this composite was lowest for those assigned to low-dose lamifiban (P = 0. The event reduction was greatest in patients at greatest risk of thrombotic complications, as suggested by raised troponin levels. These studies have utilized many different trial designs and definitions for clinical endpoints that must be considered in their evaluation. The trial found no reduction in the composite endpoints at 30 days and an increase in bleeding from abciximab treatment (51). The incidence of the composite endpoint was 32% lower at 48 h in the group that received tirofiban (3. At 30 days, the frequency of the composite endpoint (with the addition of readmission for unstable angina) was similar in the two groups (15. The use of these agents was associated with a mortality reduction that was already apparent at 30 days, from 4. However, heparin plus abciximab was associated with significantly more major bleeding than bivalirudin (4. At 30 days, a 35% relative reduction in the rate of the primary composite endpoint (12. Although patients receiving tirofiban experienced fewer events at 48 h and at 7 days (38% and 27% relative reduction, respectively), the reduction in primary composite endpoint was non-significant at 30 days. When repeat angioplasty or coronary artery bypass surgery procedures were included in the composite only if performed on an urgent or emergency basis, the composite 30-day event rates were 10. At 30 days, there was no difference in primary endpoint between the two groups (5. In the combination group there was a reduction in the composite endpoint of deaths or non-fatal reinfarction in the combination group compared to reteplase alone (8. On the other hand, these benefits were partly counterbalanced by increased non-intracranial bleeding complications in the combination group (4. The rates of intracranial haemorrhage and non-fatal disabling stroke were similar in both groups. In those over the age of 75 years the risk of major bleeds was the greatest, with a threefold increase compared to younger patients.

Rizatriptan 10 mg line. Screaming from pain puppy rescued with torn ear.

References